Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
JCR Pharmaceuticals Co Ltd
4552JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan. Address: 3-19 Kasuga-cho, Ashiya, Japan, 659-0021
Analytics
Precio Objetivo de WallStreet
134 071.71 JPYRelación P/E
–Rentabilidad por dividendo
3.26 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 4552
Análisis de dividendos 4552
Aumento del dividendo durante 5 años
196 %Crecimiento continuo
2 añoRatio de pago medio en 5 años
43 %Tendencia del payout 4552
Valoración de la acción 4552
Finanzas 4552
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |